PMC6333124_01
Platelet counts of patient 1 after initiation of eltrombopag therapy on 3 August 2015, are shown. The therapy was interrupted twice due to insurance-related problems (periods shown in red) and once due to an administration error (shown in orange). Platelet counts were low at the end of each interruption but recovered quickly after reinitiation of eltrombopag therapy. On 17 January 2017, eltrombopag was successfully discontinued, and the patient has since been in remission with stable platelet counts. QOD, every other day
CCR3-7-196-g001.jpg
PMC6333124_01_CCR3-7-196-g001.jpg
ccr31916-fig-0001
Within 2 weeks, the patient demonstrated a robust response, with her platelet count increasing to 220 x 109/L (Figure 1).
PMC6333124_02
Available platelet (blue) and absolute neutrophil (orange) count results for patient 2 after initiation of eltrombopag therapy on 2 September 2015, are shown. Platelet counts rapidly improved after initiation of eltrombopag therapy and were maintained at >200 x 109/L throughout the treatment. Absolute neutrophil counts (ANCs) increased approximately 8-9 mo after the initiation of eltrombopag therapy and continued to improve throughout the therapy. At the patient's last several visits, she had absolute neutrophil and platelet counts in the normal range. QOD, every other day
CCR3-7-196-g002.jpg
PMC6333124_02_CCR3-7-196-g002.jpg
ccr31916-fig-0002
After approximately 19 months of persistent or worsening thrombocytopenia and neutropenia, she was treated with eltrombopag in September 2015 and had a remarkably good response: an increase in platelet count from 17 x 109/L to 510 x 109/L within 2 weeks (Figure 2). The patient's neutropenia also improved during the course of eltrombopag treatment (Figure 2).